Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeCLINICAL TRIALS, STUDIES, DATAAMNIOX Highlights Three Studies Demonstrating Effectiveness of Umbilical Cord Tissue for Treating...

AMNIOX Highlights Three Studies Demonstrating Effectiveness of Umbilical Cord Tissue for Treating Chronic Wounds

April 7, 2017

AMNIOX Medical, Inc., a TissueTech, Inc. company, highlighted the publication of three studies concerning NEOX CORD 1K, its cryopreserved human umbilical cord tissue.

In contrast to competitive offerings, these studies document the consistent effectiveness of the Company’s proprietary technology in the treatment of hard-to-heal chronic wounds.

The studies include:

  • A Single-center, Retrospective Study of Cryopreserved Umbilical Cord/Amniotic Membrane Tissue for the Treatment of Diabetic Foot Ulcers in The Journal of Wound Care,
  • A Single-center, Retrospective Study of Cryopreserved Umbilical Cord for Wound Healing in Patients Suffering From Chronic Wounds of the Foot and Ankle in Wounds,
  • A Retrospective Study of Cryopreserved Umbilical Cord as an Adjunctive Therapy to Promote the Healing of Chronic, Complex Foot Ulcers with Underlying Osteomyelitis in Wound Repair and Regeneration,

The first study’s author, Dr. Allen Raphael, Northside Hospital, Atlanta, Georgia, conducted a retrospective review of 29 patients and the effectiveness of NEOX® CORD 1K Wound Allograft in treating chronic diabetic foot ulcers. Twenty-eight of 32 wounds demonstrated complete healing, to achieve a rate of 87.5 percent.

The second study’s author, Dr. Mark Couture, Medical Director of the Central Texas Prevention of Amputations for Veterans Everywhere (PAVE) program, Temple, Texas, reviewed NEOX CORD 1K Wound Allograft in treating 57 patients with chronic, lower-extremity ulcers. Fifty-one of 64 wounds, or 79.7 percent, achieved complete healing.

The final study’s author, Dr. Wayne Caputo, Chairman of the Department of Podiatric Surgery at Clara Maass Medical Center, Belleville, New Jersey, conducted a retrospective review of NEOX CORD 1K Wound Allograft in treating lower extremity ulcers with exposed bone, tendon, muscle, or joint capsule with underlying osteomyelitis in 31 patients. Of 33 wounds, 26 achieved complete healing, resulting in a healing rate of 78 percent.

“The clinical evidence surrounding our proprietary cryopreserved umbilical cord tissue in regenerative healing continues to build on the work of leading physicians,” said Tom Dugan, Chief Executive Officer of Amniox Medical. “If one compares the healing rates found in these studies with rates published for multiple alternatively processed amniotic membrane products, including bioengineered skin substitutes and cryopreserved or dehydrated amniotic membrane, these results are all the more striking. This data combined with the ease of use and flexible storage that NEOX CORD 1K offers makes it a very compelling option.”

In utero, wound healing occurs rapidly and with minimal scar. This restorative ability is innate to placental tissues, including umbilical cord and amniotic membrane. Heavy chain hyaluronic acid/pentraxin-3 is the key protein complex present in these tissues to orchestrate the healing process. Amniox Medical is the first provider of a human tissue allograft composed of both umbilical cord and amniotic membrane. Amniox utilizes its proprietary CryoTek™ process, a cryopreservation technology, to preserve the biological and structural integrity of the native tissue and published studies have demonstrated that the CryoTek process more effectively preserves the structural and biological integrity of the tissue when compared to other technologies.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

By using this website you agree to accept Medical Device News Magazine Privacy Policy